Patents by Inventor John M. Yanni

John M. Yanni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
    Patent number: 8673873
    Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: March 18, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • Method of treating otic infections with moxifloxacin compositions
    Patent number: 8673902
    Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: March 18, 2014
    Assignee: Alcon Pharmaceuticals, Ltd.
    Inventors: Gerald Cagle, Robert L. Abshire, David W. Stroman, John M. Yanni
  • Compositions Containing Moxifloxacin for Treating Otic Infections
    Publication number: 20140051670
    Abstract: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
    Type: Application
    Filed: October 25, 2013
    Publication date: February 20, 2014
    Inventors: Gerald Cagle, Robert L. Abshire, David W. Stroman, John M. Yanni
  • RNAi-mediated inhibition of histamine receptor H1-related conditions
    Patent number: 8618278
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: December 31, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
    Publication number: 20130338213
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: August 22, 2013
    Publication date: December 19, 2013
    Applicant: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • TREATMENT FOR MICROBE-INDUCED INFLAMMATORY RESPONSES IN THE EYE
    Publication number: 20130274216
    Abstract: The present invention relates to ophthalmic compositions comprising inhibitors of spleen tyrosine kinase (syk). The compositions are particularly well suited for the treatment of ophthalmic infection such as fungal keratitis. The compositions optionally comprise an antiinfective compound such as an antibacterial or antifungal compound. The present invention also relates to methods for treating fungal keratitis using compositions comprising syk inhibitors.
    Type: Application
    Filed: April 12, 2013
    Publication date: October 17, 2013
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Eric C. Carlson, Mark R. Hellberg, John M. Yanni
  • RNAi-mediated inhibition of tumor necrosis factor ?-related conditions
    Patent number: 8541389
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: September 24, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller
  • BICYCLIC HETEROARYL INHIBITORS OF PDE4
    Publication number: 20130045975
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: February 10, 2012
    Publication date: February 21, 2013
    Applicant: KALYPSYS, INC.
    Inventors: Steven P. Govek, Clay Beauregard, Daniel A. Gamache, Mark R. Hellberg, Stewart A. Noble, Andrew K. Shiau, David J. Thomas, John M. Yanni
  • RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions
    Publication number: 20120264809
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Application
    Filed: June 11, 2012
    Publication date: October 18, 2012
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of histamine receptor H1-related conditions
    Patent number: 8222227
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: July 17, 2012
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
    Patent number: 8138205
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: March 20, 2012
    Assignee: Kalypsys, Inc.
    Inventors: Steven P. Govek, Clay Beauregard, Daniel A. Gamache, Mark R. Hellberg, Stewart A. Noble, Andrew K. Shiau, David J. Thomas, John M. Yanni
  • HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
    Publication number: 20120065187
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.
    Type: Application
    Filed: November 21, 2011
    Publication date: March 15, 2012
    Applicants: ALCON RESEARCH, LTD, KALYPSYS, INC.
    Inventors: Allen J. Borchardt, Clay Beauregard, Travis Cook, Robert L. Davis, Daniel A. Gamache, John M. Yanni
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALLERGY
    Publication number: 20120015953
    Abstract: The present invention relates to compositions comprising an antagonist of the histamine H1 receptor and a compatible antagonist of the histamine H4 receptor. The antagonist compounds are selected to prevent the H4 receptor antagonist from interfering with the H1 receptor antagonist's suppression of acute phase allergic responses in a patient. The present invention also relates to compositions comprising a mast cell stabilizer and a compatible antagonist of the histamine H4 receptor.
    Type: Application
    Filed: July 14, 2011
    Publication date: January 19, 2012
    Inventors: Clay Beauregard, Peter G. Klimko, John M. Yanni, Daniel A. Gamache
  • RNAi-Mediated Inhibition of Spleen Tyrosine Kinase-Related Inflammatory Conditions
    Publication number: 20110288157
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Application
    Filed: June 30, 2011
    Publication date: November 24, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions
    Publication number: 20110269822
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Application
    Filed: June 30, 2011
    Publication date: November 3, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
    Patent number: 8048863
    Abstract: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: November 1, 2011
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • RNAi-mediated inhibition of histamine receptor H1-related conditions
    Patent number: 8017592
    Abstract: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: September 13, 2011
    Assignee: Alcon Research, Ltd.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • METHOD OF ACCELERATING CORNEAL WOUND HEALING
    Publication number: 20110207809
    Abstract: The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed.
    Type: Application
    Filed: February 25, 2011
    Publication date: August 25, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Eric C. Carlson, Daniel A. Gamache, Mark R. Hellberg, Peter G. Klimko, Kerry L. Markwardt, John M. Yanni
  • Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders
    Publication number: 20110160308
    Abstract: Compositions and methods for treating disorders of the outer retina with compounds that inhibit monoamine oxidase are disclosed.
    Type: Application
    Filed: July 27, 2007
    Publication date: June 30, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Robert J. Collier, JR., Michael A. Kapin, John M. Yanni
  • RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS
    Publication number: 20110142767
    Abstract: RNA interference is provided for inhibition of tumor necrosis factor ? (TNF?) by silencing TNF? cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF? converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF? targets, in particular, is useful for treating patients having a TNF?-related condition or at risk of developing a TNF?-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
    Type: Application
    Filed: February 25, 2011
    Publication date: June 16, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Daniel A. Gamache, Steven T. Miller